[Compound nylestriol tablet to prevent bone loss in osteoporotic rats]

Area of Science:

• Pharmacology
• Endocrinology
• Bone Biology

Background:

• Osteoporosis is a significant health concern, characterized by bone loss.
• Retinoic acid (RA) and ovariectomy (OVX) are established methods for inducing osteoporotic rat models.
• Estrogen deficiency and certain retinoids can negatively impact bone mineral density.

Purpose of the Study:

• To evaluate the efficacy of compound nylestriol tablet (CNT) in preventing bone loss.
• To compare the effects of CNT with its individual components, nylestriol (NYL) and levonorgestrel (LEV).
• To assess CNT's impact on bone mineral density and biochemical markers in established osteoporotic rat models.

Main Methods:

• 144 female SD rats (7-month-old) and 120 female SD rats (4-month-old) were used, divided into 12 and 10 groups, respectively.
• Osteoporosis was induced using retinoic acid (RA) or ovariectomy (OVX).
• Rats were treated with varying doses of CNT, NYL, or LEV daily, and serum markers, bone mineral density (BMD), and bone calcium/phosphate levels were measured.

Main Results:

• Both RA and OVX successfully induced osteoporotic models in rats.
• CNT, nylestriol (NYL), and levonorgestrel (LEV) demonstrated preventive effects against bone loss in both models.
• CNT exhibited a dose-dependent preventive effect, which was superior to that of its individual components, with moderate to high doses showing the strongest impact.

Conclusions:

• Compound nylestriol tablet (CNT) therapy is effective in preventing bone loss in both retinoic acid-induced and ovariectomy-induced osteoporotic rat models.
• CNT demonstrates superior therapeutic and preventive effects compared to nylestriol or levonorgestrel when used alone.
• The findings suggest a potential therapeutic application for CNT in managing osteoporosis.